Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00734435 · ClinicalTrials.gov registry record · Phase 2
Olanzapine Given in Combination With Zonisamide SR to Prevent Weight Gain in Schizophrenic Subjects
A Phase 2 study, sponsored by Orexigen Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
NCT00734435: Clinical Trial Phase 2 study, sponsored by Orexigen Therapeutics.
NCT00734435 is a Phase 2 study that was terminated before completion, run by Orexigen Therapeutics. The registered enrollment target is 26 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00734435, a Phase 2 study, was terminated before completion, sponsored by Orexigen Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if zonisamide SR will prevent weight gain in schizophrenic subjects who take olanzapine (Zyprexa)
Interventions
- DRUG zonisamide SR plus olanzapine
- DRUG Placebo plus olanzapine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2008-09 |
| Est. Completion | 2008-12 |
| Phase | Phase 2 |
Why NCT00734435 stopped before completion
NCT00734435 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 2 interventions - of which zonisamide SR plus olanzapine is the first listed.
NCT00734435 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00734435 about?
NCT00734435 is a clinical study titled "Olanzapine Given in Combination With Zonisamide SR to Prevent Weight Gain in Schizophrenic Subjects". The purpose of this study is to determine if zonisamide SR will prevent weight gain in schizophrenic subjects who take olanzapine (Zyprexa)
What is the current status of trial NCT00734435?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2008-09. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00734435?
The interventions under investigation include: zonisamide SR plus olanzapine (DRUG), Placebo plus olanzapine (DRUG).
Who is sponsoring clinical trial NCT00734435?
This trial is sponsored by Orexigen Therapeutics, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00734435's enrollment target sits among peer trials
26 1708th of 2000 higher than 282 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia